Focus: Amrif is an early-stage biotech focused on developing therapies for chronic diseases driven by systemic inflammation, with a specialized immunology focus. Founded in 2022 and headquartered in Wageningen, Netherlands, the company operates as a pre-revenue biotech with no disclosed employee count.
Profile data last refreshed 23h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Amrif to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Amrif
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Amrif's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo